• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型B结构域缺失重组因子VIII分子。构建与生化特性分析。

Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.

作者信息

Lind P, Larsson K, Spira J, Sydow-Bäckman M, Almstedt A, Gray E, Sandberg H

机构信息

Pharmacia AB, Biopharmaceuticals, Stockholm, Sweden.

出版信息

Eur J Biochem. 1995 Aug 15;232(1):19-27. doi: 10.1111/j.1432-1033.1995.tb20776.x.

DOI:10.1111/j.1432-1033.1995.tb20776.x
PMID:7556150
Abstract

Recombinant molecules similar to the smallest active plasma-derived factor VIII molecule, a complex of an 80-kDa and a 90-kDa polypeptide chain lacking the B domain, have been produced using various factor VIII cDNA constructs in order to obtain primary translation products which were efficiently processed into the 80 + 90-kDa complex. Three types of single-chain cDNAs encoding B-domain-deleted derivatives factor VIII were designed, taking account of sites at Arg740 and Glu1649, assumed to be important for processing factor VIII. In the type 1 constructs, either Arg747, Arg752, or Arg776 in the N-terminal region of factor VIII B domain was fused to the N-terminus (Glu1649) of the 80-kDa subunit. In the type 2 construct r-VIII SQ, Ser743 was fused to Gln1638, creating a link of 14 amino acids between the C-terminus (Arg740) of the 90-kDa chain and N-terminus of the 80-kDa chain, whereas in type 2 r-VIII RH, Arg747 was fused to His1646. In the type 3 constructs, the B-domain was completely removed or replaced with 1-4 Arg residues. After expression in Chinese hamster ovary cells, the type 1 derivatives and the type 3 derivatives with 0-2 Arg residues inserted were found to be only partially processed and contained a large amount of the 170-kDa primary translation product. In contrast, most of the type 2 derivatives r-VIII SQ and r-VIII RH and the type 3 derivatives r-VIII R4 and r-VIII R5 containing three or four extra Arg residues preceding the N-terminus of the 80-kDa chain were processed into the desired 80 + 90-kDa chain complexes. The feature common to the most efficiently processed factor VIII deletion derivatives was that they contained the recognition motif for proteolytic cleavage by the membrane-bound subtilisin-like protease furin, which is expressed in most types of cells; that is, basic amino acid residues at positions -1 and -4 relative to the cleavage site at Glu1649. Biochemical studies of r-VIII SQ and r-VIII R5, two of the most effectively processed factor VIII derivatives, showed that both proteins had a normal factor VIII cofactor function, and had N- and C-termini of the 80-kDa and 90-kDa chains corresponding to those found in plasma-derived factor VIII.

摘要

为了获得能有效加工成80 + 90 kDa复合物的初级翻译产物,已使用各种因子VIII cDNA构建体生产了与最小活性血浆来源的因子VIII分子(一种由80 kDa和90 kDa多肽链组成且缺少B结构域的复合物)相似的重组分子。考虑到假定对因子VIII加工很重要的Arg740和Glu1649位点,设计了三种编码B结构域缺失的因子VIII衍生物的单链cDNA。在1型构建体中,因子VIII B结构域N端区域的Arg747、Arg752或Arg776与80 kDa亚基的N端(Glu1649)融合。在2型构建体r-VIII SQ中,Ser743与Gln1638融合,在90 kDa链的C端(Arg740)和80 kDa链的N端之间形成了14个氨基酸的连接,而在2型r-VIII RH中,Arg747与His1646融合。在3型构建体中,B结构域被完全去除或被1 - 4个Arg残基取代。在中国仓鼠卵巢细胞中表达后,发现1型衍生物和插入0 - 2个Arg残基的3型衍生物仅被部分加工,并且含有大量170 kDa的初级翻译产物。相比之下,大多数2型衍生物r-VIII SQ和r-VIII RH以及在80 kDa链N端之前含有三个或四个额外Arg残基的3型衍生物r-VIII R4和r-VIII R5被加工成了所需的80 + 90 kDa链复合物。加工效率最高的因子VIII缺失衍生物的共同特征是它们含有膜结合的枯草杆菌蛋白酶样蛋白酶弗林蛋白酶(furin)进行蛋白水解切割的识别基序,弗林蛋白酶在大多数类型的细胞中都有表达;也就是说,相对于Glu1649处切割位点的 - 1和 - 4位的碱性氨基酸残基。对加工最有效的两种因子VIII衍生物r-VIII SQ和r-VIII R5的生化研究表明,这两种蛋白都具有正常的因子VIII辅因子功能,并且80 kDa和90 kDa链的N端和C端与血浆来源的因子VIII中的对应端相同。

相似文献

1
Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.新型B结构域缺失重组因子VIII分子。构建与生化特性分析。
Eur J Biochem. 1995 Aug 15;232(1):19-27. doi: 10.1111/j.1432-1033.1995.tb20776.x.
2
Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ.缺失B结构域的重组凝血因子VIII蛋白r-VIII SQ的结构与功能特性
Thromb Haemost. 2001 Jan;85(1):93-100.
3
Amino acid residues 721-729 are required for full factor VIII activity.氨基酸残基721 - 729是凝血因子VIII全活性所必需的。
Eur J Biochem. 1995 Dec 15;234(3):773-9. doi: 10.1111/j.1432-1033.1995.773_a.x.
4
Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.新型重组因子VIII(缺乏大部分B结构域的因子VIII-δII)的结构与功能特性
Biochem J. 1991 Jul 1;277 ( Pt 1)(Pt 1):23-31. doi: 10.1042/bj2770023.
5
Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.缺乏中央B结构域及重链序列Lys713 - Arg740的重组因子VIII变体的生物学活性:体外和体内活性不一致
Br J Haematol. 1993 Sep;85(1):133-42. doi: 10.1111/j.1365-2141.1993.tb08656.x.
6
Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII delta II.一种新型抗血友病因子变体——凝血因子VIII δII的凝血酶切割分析
Eur J Biochem. 1991 Feb 14;195(3):637-44. doi: 10.1111/j.1432-1033.1991.tb15748.x.
7
Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system.在中国仓鼠卵巢细胞中,基于改良的延伸因子-1α系统实现因子VIII的稳定高水平表达。
BMC Biotechnol. 2017 Mar 24;17(1):33. doi: 10.1186/s12896-017-0353-6.
8
Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r)).两种血友病因子VIII变体C329S(CRM(-))和G1948D(CRM(r))的稳定重组表达及特性分析
Br J Haematol. 2001 Jun;113(3):604-15. doi: 10.1046/j.1365-2141.2001.02399.x.
9
Efficient production of recombinant human factor VIII by co-expression of the heavy and light chains.
Protein Eng. 1993 Aug;6(6):669-74. doi: 10.1093/protein/6.6.669.
10
Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.rVIII-SingleChain 的理化特性,一种新型的重组单链因子 VIII。
Thromb Res. 2015 Aug;136(2):388-95. doi: 10.1016/j.thromres.2015.05.005. Epub 2015 May 16.

引用本文的文献

1
Current clinical applications of AAV-mediated gene therapy.腺相关病毒介导的基因治疗的当前临床应用。
Mol Ther. 2025 Jun 4;33(6):2479-2516. doi: 10.1016/j.ymthe.2025.04.045. Epub 2025 May 5.
2
Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis.斑马鱼中凝血因子 VIII 的缺失可重新平衡抗凝血酶缺乏,但出血素质有限。
Blood Adv. 2025 Jul 8;9(13):3136-3148. doi: 10.1182/bloodadvances.2024013143.
3
Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis.
斑马鱼中凝血因子 VIII 的缺失可重新平衡抗凝血酶缺乏,但出血素质有限。
bioRxiv. 2024 Mar 3:2024.02.28.582609. doi: 10.1101/2024.02.28.582609.
4
Coagulation factor VIII: biological basis of emerging hemophilia A therapies.凝血因子 VIII:新兴血友病 A 治疗方法的生物学基础。
Blood. 2024 Nov 21;144(21):2185-2197. doi: 10.1182/blood.2023023275.
5
Cellular stress and coagulation factor production: when more is not necessarily better.细胞应激与凝血因子生成:过犹不及。
J Thromb Haemost. 2023 Dec;21(12):3329-3341. doi: 10.1016/j.jtha.2023.10.005. Epub 2023 Oct 14.
6
Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner.VIII 因子抗体免疫复合物以表位依赖的方式调节对 VIII 因子的体液免疫反应。
Front Immunol. 2023 Aug 31;14:1233356. doi: 10.3389/fimmu.2023.1233356. eCollection 2023.
7
Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.因子 VIII B 结构域和酸性区域 3 界面的切割改变增强了血友病 A 小鼠基因治疗后的表达。
J Thromb Haemost. 2023 Aug;21(8):2101-2113. doi: 10.1016/j.jtha.2023.04.012. Epub 2023 Apr 18.
8
The Arrival of Gene Therapy for Patients with Hemophilia A.基因治疗血友病 A 患者时代的到来。
Int J Mol Sci. 2022 Sep 6;23(18):10228. doi: 10.3390/ijms231810228.
9
Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy.在当前血友病 A 基因治疗的治疗环境中 BAY 2599023 的特点。
Curr Gene Ther. 2023;23(2):81-95. doi: 10.2174/1566523222666220914105729.
10
Adeno-Associated Virus Gene Therapy for Hemophilia.腺相关病毒基因治疗血友病。
Annu Rev Med. 2023 Jan 27;74:231-247. doi: 10.1146/annurev-med-043021-033013. Epub 2022 Sep 14.